ArticleBiomimetics (Basel, Switzerland)2025
In Vivo Vascularization of Cell-Supplemented Spider Silk-Based Hydrogels in the Arteriovenous Loop Model.
Article in Biomimetics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biofabrication of Endothelialized, Intrinsically Vascularized 3D-Printed Recombinant Spider Silk Scaffolds.Advanced healthcare materials · 2026Article
- Nanostructured Protein Surfaces Inspired by Spider Silk.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Biofabrication of 3D-printed, pre-cross-linked alginate dialdehyde-gelatin (ADA-GEL) scaffolds for anFrontiers in bioengineering and biotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
The goal of reconstructive surgery in treating tissue defects is to achieve a stable reconstructive outcome while minimizing donor site morbidity. As a result, tissue engineering has emerged as a key focus in the pursuit of this goal. One approach is to create a tissue container that can be preconditioned and later transplanted into the defect area. The characteristics of the matrices used in the tissue container are critical to this approach's success. Matrices generated with recombinant, functionalized spider silk (eADF4(C16)-RGD) have been reported to be biocompatible and easy to vascularize. However, the effect of exogenously added proangiogenic cells, such as endothelial cells (T17b), on the vascularization process of matrices generated with this hydrogel in vivo has not been described yet. In this study, we implanted arteriovenous (AV) loop containers filled with a spider silk hydrogel consisting of an eADF4(C16)-RGD matrix and encapsulated, differentiated endothelial T17b cells producing the reporter protein TNFR2-Fc-Flag-GpL. The histological and µCT analyses revealed spontaneous angiogenesis and fibrovascular tissue formation in the container at 2 and 4 weeks post-implantation. The reporter protein was detected after 4 weeks. No severe immune response was observed. Altogether, this study demonstrates that cell-supplemented recombinant spider silk is a highly promising hydrogel to produce matrices for tissue engineering applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.